THERMO FISHER SCIENTIFIC INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $TMO in the last 30 days.
See all $TMO insider activity →Thermo Fisher Scientific Inc. shares rose 1.64% to $684.89 on Monday, outperforming the S&P 500 and Dow Jones. This ended a two-day losing streak for the stock.
Costa Rica received $5.12B in foreign direct investment in 2025, with 54.8% from the U.S. Medical devices were the largest export. Key investors include Boston Scientific, Medtronic, Intel, and Bayer. The free-zone regime, offering tax incentives, attracted 66.4% of investments. The U.S. is the top trading and security partner, while China, the IMF, and the World Bank have narrower roles.
Thermo Fisher Scientific reported Q3 revenue of $12.14B, up 9% YoY, with shares reaching a record $705.79. Analysts raised target prices. Growth was driven by new products and AI initiatives, including a collaboration with Nvidia. The company also integrated Clario to expand clinical services. Revenue sources include lab consumables (52%) and high-growth areas like mass spectrometry and sequencing. AI and clinical data services are key focus areas for future growth.
Over the past 7 days, AlphAI's AI scored 18 news stories mentioning TMO (THERMO FISHER SCIENTIFIC INC.). Coverage has skewed bullish: 13 bullish, 5 neutral, and 0 bearish.
Recent TMO coverage spans financial news, earnings and market movers.
The modest price gain reflects short‑term buying pressure without a disclosed catalyst.
The article indicates participation in Costa Rica projects but does not provide company-specific milestones or investment figures.
Strong earnings beat and upgraded targets suggest upside pressure.
The target raise suggests bullish sentiment and could drive buying pressure.
Thermo Fisher's guidance was already released; the article provides no new information.
AlphAI scores every news story that mentions TMO with an AI model for sentiment and relevance, and aggregates insider trades from THERMO FISHER SCIENTIFIC INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Thermo Fisher Scientific Inc. shares rose 1.64% to $684.89 on Monday, outperforming the S&P 500 and Dow Jones. This ended a two-day losing streak for the stock.
1 min readCosta Rica received $5.12B in foreign direct investment in 2025, with 54.8% from the U.S. Medical devices were the largest export. Key investors include Boston Scientific, Medtronic, Intel, and Bayer. The free-zone regime, offering tax incentives, attracted 66.4% of investments. The U.S. is the top trading and security partner, while China, the IMF, and the World Bank have narrower roles.
8 min readThermo Fisher Scientific reported Q3 revenue of $12.14B, up 9% YoY, with shares reaching a record $705.79. Analysts raised target prices. Growth was driven by new products and AI initiatives, including a collaboration with Nvidia. The company also integrated Clario to expand clinical services. Revenue sources include lab consumables (52%) and high-growth areas like mass spectrometry and sequencing. AI and clinical data services are key focus areas for future growth.
3 min readCitigroup maintained a 'Buy' rating for Thermo Fisher Scientific (TMO) and raised its price target to $800 from $685. TMO is currently priced at $670.66, which is 9.8% overvalued compared to its GF Value™ of $610.82. The company has a GF Score™ of 84/100, indicating strong overall performance, but insider activity shows significant selling. TMO operates in the healthcare sector, with a market capitalization of approximately $247.97 billion.
2 min readIllumina (ILMN) and Thermo Fisher (TMO) both serve drug developers and labs. ILMN raised its 2026 revenue forecast to $4.62B, citing strong clinical market growth. TMO reported 9% Q3 revenue growth and raised its 2026 guidance to $47.7B-$48.2B. ILMN has higher margins and lower debt, while TMO shows faster growth and a lower P/E ratio.
2 min readWall Street analyst research calls for Friday include upgrades for Hess Midstream LP (HESM) to Outperform, MSC Industrial (MSM) to Overweight, and SpaceX (SPCX) to Buy. Downgrades include Deckers Outdoor (DECK) to Underweight, Globe Life (GL) to Neutral, and NVR (NVR) to Underperform. Initiations include Guardant Health (GH) and Natera (NTRA) with Buy ratings. Markets saw declines, with Nasdaq down 2.6% and Treasury yields dropping sharply.
3 min readBarclays maintained an 'Overweight' rating for Thermo Fisher Scientific (TMO) and raised its price target from $750 to $775. TMO's current price of $680.13 is 12.6% above its GF Value™ of $604.24, indicating potential overvaluation. The company has a GF Score™ of 84/100, showing strong performance but concerns in financial strength. Insider selling totaled $61.56M over the past three months.
1 min readRBC Capital maintained a 'Sector Perform' rating for Thermo Fisher Scientific (TMO) but raised its price target to $730 from $580. The stock is currently trading at $681.41, which is 12.8% overvalued according to GuruFocus's GF Value™. TMO has a GF Score™ of 84/100, indicating strong performance relative to peers. Insider activity shows significant selling, with $61.56 million in insider sell value over the past three months.
2 min readTD Cowen kept a Buy rating on Thermo Fisher Scientific with an $810 price target, suggesting a 16.7% upside. The company reported 6% organic revenue growth in Q3, raised full-year guidance, and expects margin expansion. According to TD Cowen, this reflects strong demand and operational efficiency.
1 min readStifel raised its price target for Thermo Fisher Scientific to $775 from $650. The stock has gained 19.77% year-to-date and 3.09% in the past month. Bernstein also increased its target to $675 from $575.
1 min read
